Skip to content

Clinical observation study on the treatment of infusion phlebitis by external application of Liu Shen vinegar liquid

Clinical observation study on the treatment of infusion phlebitis by external application of Liu Shen vinegar liquid

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002017
Enrollment
Unknown
Registered
2025-10-28
Start date
2024-12-30
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with infusion phlebitis

Interventions

Six Gods Vinegar Liquid External Application Group (Group A):Each time, 10 grains of Liushen Pills (Shanghai Lei Yun Shang Pharmaceutical Co., Ltd., 1000 grains, 3.125g) were finely ground, and 2ml of
50 per cent magnesium sulphate wet pack group (group B):A 50% magnesium sulphate solution (Tsuyoshi Peace Pharmaceutical Co., Ltd., 10 ml, 5 g) was used by the nurse-in-charge, warmed up and applied e
Jinhuang paste external application group (Group C):Jinhuang Ointment (composed of smallpox pollen, rhubarb, cypress, turmeric, Angelica dahurica, shengnanxing, chenpi, atractylodes macrocephala, Houp

Sponsors

Yueyang Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Patients with phlebitis who met the phlebitis grade =1 in the Infusion Nurses Society (INS) 8th edition of the Infusion Therapy Practice Standards, 2021 [19]; and (2) 18 years old = age = 80 years old, gender is not limited; (3) Clear consciousness, with normal language expression ability; (4) Voluntarily participated in this study and signed an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Persons with a known allergy to the test drug in this study; (2) Persons with oedema of the upper limbs, skin lesions at the site of venipuncture, inflammation or rash, or other diseases; (3) Severe cardiac, cerebral or renal disease or other life-threatening diseases; (4) Deterioration of the condition with complications in other organs; (6) Neuropsychiatric system diseases and those who are unable to cooperate with the treatment; (7) Those who use other ointments for external application (e.g. Xifengtou, etc.). (8) Preparation for pregnancy, pregnancy, breastfeeding patients.

Design outcomes

Primary

MeasureTime frame
overall effectiveness rate;

Secondary

MeasureTime frame
Average time to cure;Pain scores;

Countries

China

Contacts

Public ContactShenyonghong

Yueyang Hospital of Integrative Medicine, Shanghai University of Traditional Chinese

Shenyonghong728@163.com+86 189 3056 8122

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026